The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy
Launched by INCREDIWEAR HOLDINGS, INC. · Feb 20, 2025
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Extensor Carpi Radialis Brevis (ECRB) tendinopathy, also known as lateral epicondylitis or tennis elbow, is the most prevalent elbow soft tissue injury and affects 1-3% of the population. Repetitive overloading of the tendon and ligaments in the elbow lead to microtraumas, causing abnormal angiofibroblastic remodeling and increased pain. Microtearing occurs most commonly at the origin of the extensor carpi radialis brevis (ECRB) tendon. The main symptoms include a loss of grip strength, a burning sensation near the ECRB origin site, and pain during daily activities such as grasping objects ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients diagnosed with ECRB tendinopathy as determined by radiographic assessment or ultrasound imaging.
- • 2. Patients age 18-65
- • 3. Patients who are willing and able to adhere to follow-up schedule and protocol guidelines.
- • 4. Patients who are willing and able to sign corresponding research subject consent form.
- Exclusion Criteria:
- • 1. Patient has a history of neurological conditions, including multiple sclerosis or Parkinson's disease
- • 2. Patient has severe medical condition, including recent myocardial infarction, unstable angina, heart failure, severe anemia
- • 3. Patient has had prior surgical treatment of the elbow in the last 5 years or injection treatment(s) in the last 2 years
- • 4. Patient has complete tear of ECRB tendon or other surgical indication
- • 5. Patient has chronic pain conditions unrelated to elbow condition
- • 6. Patient has auto-immune or auto-inflammatory diseases
- • 7. Patient has used tobacco within the last 90 days
- • 8. Patient is not within the ages of 18-65
- • 9. Patient has a history of metabolic disorders
- • 10. Patient has an active infection (local or systemic)
- • 11. Patient is unwilling or unable to sign the corresponding research subject consent form
- • 12. Patient meets any other criteria or has any other condition that, in the opinion of the investigator, would prevent them from completing the study or that, in the opinion of the investigator, would confound study results.
About Incrediwear Holdings, Inc.
Incrediwear Holdings, Inc. is a pioneering healthcare company focused on developing innovative wearable technology designed to enhance recovery and improve overall well-being. Leveraging advanced materials and cutting-edge design, Incrediwear’s products aim to provide therapeutic benefits for individuals experiencing pain, inflammation, and discomfort due to various health conditions. Committed to clinical research, the company actively sponsors clinical trials to validate the efficacy of its solutions, ensuring that their offerings are backed by scientific evidence and tailored to meet the needs of patients and healthcare providers alike. With a mission to improve quality of life through effective and non-invasive therapies, Incrediwear Holdings, Inc. stands at the forefront of the wearable health revolution.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chesterfield, Missouri, United States
Patients applied
Trial Officials
Dr. Matthew Bayes, MD, Medical
Principal Investigator
Bluetail Medical Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported